Glibenclamide nanosuspension inhaler: development, and assessment.

The development of nanosuspension for targeted delivery of glibenclamide as hypoglycemic agent to the lung in an inhaler dosage form. Glibenclamide nanosuspension formulations were prepared using Box-Behnken design to investigate the effect of independent factors on the dependent variables, Fourier-transform Infrared spectroscopy, Differential Scanning Calorimetry, evaluation of glibenclamide nanosuspension inhaler and hypoglycemic efficacy were performed to determine glibenclamide nanosuspension inhaler effect. The results revealed that the mean particle sizes of the prepared nanosuspension ranged from 0.